Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled ...

    Research Article last updated 06/07/2016 - 11:10am.

  2. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald ...

    Research Article last updated 04/29/2016 - 11:34am.

  3. Myelodysplastic syndromes: Contemporary review and how we treat

    ... the hypomethylating agents (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, ...

    Research Article last updated 04/29/2016 - 1:05pm.

  4. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... hypomethylating agents (HMAs) azacitidine and decitabine are currently the most frequently administered ... syndromes (MDS). However, azacitidine and decitabine are not curative, the median response duration is 11-15 months, ...

    Research Article last updated 11/19/2015 - 8:32am.

  5. BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

    Journal Title:  Haematologica Primary Author:  Lazarini M Author(s):  Lazarin...

    Research Article last updated 11/28/2016 - 9:50am.

  6. Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... This retrospective analysis evaluated response to decitabine using updated IWG criteria in patients pooled from 2 decitabine trials. PATIENTS AND METHODS: Outcomes for patients with ...

    Research Article last updated 06/28/2013 - 1:20pm.

  7. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... AML and survival in 163 patients with MDS treated with decitabine 15 mg/m(2) over 3 hours every 8 hours for 3 days every 6 weeks ... should be considered for other interventions in addition to decitabine treatment. Bone ...

    Research Article last updated 01/02/2013 - 2:53pm.

  8. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... lenalidomide , 5- azacitidine , and decitabine . These therapies can be effective in the relief of cytopenias, ...

    Research Article last updated 05/26/2015 - 12:13pm.

  9. Personalized medicine for MDS

    ... agents, such as azacitidine and decitabine , are standard care for older patients with higher-risk MDS who ...

    Research Review last updated 05/02/2016 - 9:44am.

  10. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 05/12/2015 - 9:47am.